Previous 10 | Next 10 |
TWYNEO ® , a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide TWYNEO utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038 Un...
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quart...
Sol-Gel Technologies (SLGL) and Galderma has signed two exclusive five-year license agreements for the commercialization of Epsolay and Twyneo in the United States. Under the pact, Galderma has an exclusive license to commercialize Sol-Gel's advanced investigational drug products using Sol-Ge...
Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal model Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients ...
- Upfront and approval payments of up to $15 million - Tiered royalties ranging from mid- to high-teen percentage of net sales - Sol-Gel option to regain commercialization rights 5 years following first commercialization Sol-Gel Technologies, Ltd. (NASDAQ: SLGL),...
NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases...
Sol-Gel Technologies (SLGL): Q1 GAAP EPS of $0.18 beats by $0.63.Revenue of $0.7M (-79.8% Y/Y) misses by $0.97M.Press Release For further details see: Sol-Gel Technologies EPS beats by $0.63, misses on revenue
- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ® - EPSOLAY PDUFA goal date was set for April 26, 2021. Awaiting FDA ’s pre-approval inspection ...
Gainers: Tian Ruixiang (TIRX) +54%.Vaxart (VXRT) +51%.RiceBran Technologies (RIBT) +47%.Aldeyra Therapeutics (ALDX) +31%.NetSol Technologies (NTWK) +30%.First Choice Bancorp (FCBP) +28%.TrueBlue (TBI) +26%.Brooklyn ImmunoTherapeutics (BTX) +23%.Big Rock Partners Acquisition (BRPA) +23%.T...
Sol-Gel Technologies ([[SLGL]] -21.1%) has shed more than a fifth in value after announcing that the company received no notification from the FDA regarding its marketing application for EPSOLAY (benzoyl peroxide) 5% topical cream for adults with Inflammatory lesions of rosacea.However, ...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved larg...
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...